Analytical Data
-
Gene name
MAGEB16
- Application
-
Alternative Names
MAGEB16;Melanoma-associated antigen B16
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A2A368
-
Expression Region
1-324aa
-
AA Sequence
MSQDQESPRC THDQHLQTFS ETQSLEVAQV SKALEKTLLS SSHPLVPGKL KEAPAAKAES PLEVPQSFCS SSIAVTTTSS SESDEASSNQ EEEDSPSSSE DTSDPRNVPA DALDQKVAFL VNFMLHKCQM KKPITKADML KIIIKDDESH FSEILLRASE HLEMIFGLDV VEVDPTTHCY GLFIKLGLTY DGMLSGEKGV PKTGLLIIVL GVIFMKGNRA TEEEVWEVLN LTGVYSGKKH FIFGEPRMLI TKDFVKEKYL EYQQVANSDP ARYEFLWGPR AKAETSKMKV LEFVAKVHGS YPHSFPSQYA EALKEEEERA RARI
-
Molecular Weight
36.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEB16, a member of the MAGE (Melanoma Antigen Gene) family, has garnered significant attention in cancer research due to its potential role in tumor immunology and its expression profiles in various malignancies. Initially discovered in melanoma tissues, MAGE genes are known for their function in immune evasion, as they encode proteins that can interact with the immune system and contribute to the development of tumors. The study of MAGEB16 is particularly intriguing because it shows differential expression in several types of cancers, suggesting it may serve as a biomarker for disease diagnosis or prognosis. Furthermore, the recombinant protein form of MAGEB16 is being investigated for its potential use in immunotherapeutic strategies, such as cancer vaccines or adoptive cell therapy. Understanding the mechanisms by which MAGEB16 influences tumor growth and immune responses could offer new insights into targeted therapies. Additionally, due to its relatively restricted expression in normal tissues, MAGEB16 presents an attractive target for cancer immunotherapy, minimizing the risk of harming healthy cells. Consequently, ongoing research is focused on exploring the structural properties, immunogenicity, and cellular interactions of recombinant MAGEB16 proteins, aiming to leverage this knowledge for innovative cancer treatment modalities.











